Informações:
Falhas:
ID
17784
Descrição
Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00365768
Link
https://clinicaltrials.gov/show/NCT00365768
Palavras-chave
Versões (2)
- 02/10/2016 02/10/2016 -
- 03/10/2016 03/10/2016 -
Transferido a
3 de outubro de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Kidney Cancer NCT00365768
Eligibility Kidney Cancer NCT00365768
- StudyEvent: Eligibility
Similar models
Eligibility Kidney Cancer NCT00365768
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Age
Item
patients between the age of 5 and 21 years old.
boolean
C0001779 (UMLS CUI [1])
Assessment Complete Ability
Item
patients who demonstrate the ability to complete the assessment instruments at baseline.
boolean
C1516048 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
C0205197 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
leukemia | Solid tumour | Vincristine Cumulative Dose Expected | Vincristine individual dose
Item
patients who are diagnosed with leukemia or solid tumors and are expected to receive a cumulative dose of > or = to 6mg/m2 of vincristine, or > 6mg if individual vincristine doses are capped at 2mg according to primary cancer treatment protocol, over a 30-week period.
boolean
C0023418 (UMLS CUI [1])
C0280100 (UMLS CUI [2])
C0042679 (UMLS CUI [3,1])
C2986497 (UMLS CUI [3,2])
C1517001 (UMLS CUI [3,3])
C0042679 (UMLS CUI [4,1])
C0677260 (UMLS CUI [4,2])
C0280100 (UMLS CUI [2])
C0042679 (UMLS CUI [3,1])
C2986497 (UMLS CUI [3,2])
C1517001 (UMLS CUI [3,3])
C0042679 (UMLS CUI [4,1])
C0677260 (UMLS CUI [4,2])
Primary malignant neoplasm of central nervous system | Medulloblastoma | CNS metastases
Item
patients with primary cns tumors other than medulloblastoma or patients with cns metastasis.
boolean
C1455806 (UMLS CUI [1])
C0025149 (UMLS CUI [2])
C0686377 (UMLS CUI [3])
C0025149 (UMLS CUI [2])
C0686377 (UMLS CUI [3])
Recurrent disease
Item
patients with recurrent disease.
boolean
C0277556 (UMLS CUI [1])
Neurological status | CTCAE grade finding | examination; clinical
Item
patients with grade ii, iii or iv neurological status by the nci ctc (ver. 3.0) on clinical exam.
boolean
C0746866 (UMLS CUI [1])
C3887242 (UMLS CUI [2])
C1456356 (UMLS CUI [3])
C3887242 (UMLS CUI [2])
C1456356 (UMLS CUI [3])
Vincristine Dose | Vincristine individual dose
Item
patients who have already received > 8mg/m2 of vincristine, or > 8mg if individual vincristine doses are capped at 2mg according to primary cancer treatment protocol, during their course of therapy at time of consent.
boolean
C0042679 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0042679 (UMLS CUI [2,1])
C0677260 (UMLS CUI [2,2])
C0178602 (UMLS CUI [1,2])
C0042679 (UMLS CUI [2,1])
C0677260 (UMLS CUI [2,2])
Hepatic Encephalopathy | Hyperammonemia
Item
patients with hepatic encephalopathy or hyperammonemia.
boolean
C0019151 (UMLS CUI [1])
C0220994 (UMLS CUI [2])
C0220994 (UMLS CUI [2])
Neurological examination abnormal Focal
Item
patients with a focally abnormal neurologic exam.
boolean
C1112537 (UMLS CUI [1,1])
C0205234 (UMLS CUI [1,2])
C0205234 (UMLS CUI [1,2])